Host-pathogen interaction during bacterial vaccination.

[1]  W. Schaffner,et al.  Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. , 2015, The Lancet. Infectious diseases.

[2]  R. Rappuoli,et al.  Neisseria meningitidis: pathogenesis and immunity. , 2015, Current opinion in microbiology.

[3]  S. Fanella,et al.  Invasive Meningococcal Disease in the 21st Century—An Update for the Clinician , 2015, Current Neurology and Neuroscience Reports.

[4]  D. Levy-bruhl,et al.  Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. , 2015, Vaccine.

[5]  D. Caugant,et al.  Sequential Outbreaks Due to a New Strain of Neisseria Meningitidis Serogroup C in Northern Nigeria, 2013-14 , 2014, PLoS currents.

[6]  Ronald Anderson,et al.  Review: current and new generation pneumococcal vaccines. , 2014, The Journal of infection.

[7]  J. P. Davis,et al.  Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. , 2014, The Journal of infectious diseases.

[8]  J. Badiola,et al.  Hyper-attenuated MTBVAC erp mutant protects against tuberculosis in mice. , 2014, Vaccine.

[9]  S. Kaufmann,et al.  Central Memory CD4+ T Cells Are Responsible for the Recombinant Bacillus Calmette-Guérin ΔureC::hly Vaccine's Superior Protection Against Tuberculosis , 2014, The Journal of infectious diseases.

[10]  Johannes B. Goll,et al.  Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. , 2014, JAMA.

[11]  B. Eisele,et al.  The BCG replacement vaccine VPM1002: from drawing board to clinical trial , 2014, Expert review of vaccines.

[12]  S. Plotkin.  The pertussis problem. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  C. Locht,et al.  A Phase I Clinical Study of a Live Attenuated Bordetella pertussis Vaccine - BPZE1; A Single Centre, Double-Blind, Placebo-Controlled, Dose-Escalating Study of BPZE1 Given Intranasally to Healthy Adult Male Volunteers , 2014, PloS one.

[14]  D. Medini,et al.  Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). , 2013, Vaccine.

[15]  T. Merkel,et al.  Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model , 2013, Proceedings of the National Academy of Sciences.

[16]  B. Gicquel,et al.  Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. , 2013, Vaccine.

[17]  Z. Bhutta,et al.  Global epidemiology of invasive meningococcal disease , 2013, Population Health Metrics.

[18]  M. Maiden.  The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis? , 2013, Philosophical Transactions of the Royal Society B: Biological Sciences.

[19]  A. Pantosti,et al.  Increase of pneumococcal serotype 19A in Italy is due to expansion of the piliated clone ST416/CC199. , 2013, Journal of medical microbiology.

[20]  L. Harrison,et al.  Meningococcal Vaccines: Current Issues and Future Strategies , 2013, Drugs.

[21]  J. Cherry.  Pertussis: Challenges Today and for the Future , 2013, PLoS pathogens.

[22]  A. Pollard,et al.  Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. , 2013, Vaccine.

[23]  A. Rowhani-Rahbar,et al.  Comparative Effectiveness of Acellular Versus Whole-Cell Pertussis Vaccines in Teenagers , 2013, Pediatrics.

[24]  R. Rappuoli,et al.  Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. , 2013, The Lancet. Infectious diseases.

[25]  K. Mills,et al.  Relative Contribution of Th1 and Th17 Cells in Adaptive Immunity to Bordetella pertussis: Towards the Rational Design of an Improved Acellular Pertussis Vaccine , 2013, PLoS pathogens.

[26]  S. Kaufmann,et al.  Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. , 2013, Vaccine.

[27]  M. Pizza,et al.  Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? , 2013, Vaccine.

[28]  D. Caugant,et al.  Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  P. Rohani,et al.  Perplexities of pertussis: recent global epidemiological trends and their potential causes , 2013, Epidemiology and Infection.

[30]  S. Hugonnet,et al.  Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study , 2013, The Lancet.

[31]  F. Mooi,et al.  Small Mutations in Bordetella pertussis Are Associated with Selective Sweeps , 2012, PloS one.

[32]  Ryan T Novak,et al.  Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. , 2012, Vaccine.

[33]  A. Chandran,et al.  The Worldwide Impact of the Seven-valent Pneumococcal Conjugate Vaccine , 2012, The Pediatric infectious disease journal.

[34]  R. Link-Gelles,et al.  Pneumococcal genome sequencing tracks a vaccine escape variant formed through a multi-fragment recombination event , 2012, Nature Genetics.

[35]  D. Caugant,et al.  Postvaccination Increase in Serotype 19A Pneumococcal Disease in Norway Is Driven by Expansion of Penicillin-Susceptible Strains of the ST199 Complex , 2012, Clinical and Vaccine Immunology.

[36]  S. Clarke,et al.  13-valent pneumococcal conjugate vaccine (PCV13) , 2011, Human vaccines.

[37]  B. Gessner,et al.  Emergence of Epidemic Neisseria meningitidis Serogroup X Meningitis in Togo and Burkina Faso , 2011, PloS one.

[38]  C. Whitney,et al.  Shifting genetic structure of invasive serotype 19A pneumococci in the United States. , 2011, The Journal of infectious diseases.

[39]  T. Cherian,et al.  Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates , 2009, The Lancet.

[40]  F. Mooi,et al.  Bordetella pertussis Strains with Increased Toxin Production Associated with Pertussis Resurgence , 2009, Emerging infectious diseases.

[41]  J. Kroll,et al.  Evidence for Capsule Switching between Carried and Disease-Causing Neisseria meningitidis Strains , 2009, Infection and Immunity.

[42]  Nicholas Wood,et al.  Pertussis: review of epidemiology, diagnosis, management and prevention. , 2008, Paediatric respiratory reviews.

[43]  D. Crook,et al.  Vaccine Escape Recombinants Emerge after Pneumococcal Vaccination in the United States , 2007, PLoS pathogens.

[44]  Julian Parkhill,et al.  Genome plasticity of BCG and impact on vaccine efficacy , 2007, Proceedings of the National Academy of Sciences.

[45]  C. Whitney,et al.  Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. , 2005, The Journal of infectious diseases.

[46]  Tamara Pilishvili,et al.  Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. , 2005, JAMA.

[47]  S. Kaufmann,et al.  Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. , 2005, The Journal of clinical investigation.

[48]  K. Edwards.  Overview of Pertussis: Focus on Epidemiology, Sources of Infection, and Long Term Protection After Infant Vaccination , 2005, The Pediatric infectious disease journal.

[49]  M. Behr.  Correlation between BCG Genomics and Protective Efficacy , 2001, Scandinavian journal of infectious diseases.

[50]  P. Cieslak,et al.  Capsule switching of Neisseria meningitidis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[51]  P. E. M. Fine,et al.  Variation in protection by BCG: implications of and for heterologous immunity , 1995, The Lancet.

[52]  W. Schaffner,et al.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. , 2010, The Journal of infectious diseases.